Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Milestone Pharmaceuticals Inc. (MIST)
|
|
| Income Statement |
|
|
|
| Standardized | As Reported |
Annual | Quarterly | TTM |
|
| In millions, except per share items | Jun-30-23 | Mar-31-23 | Sep-30-22 | Jun-30-22 | Mar-31-22 | Dec-31-21 | Sep-30-21 | Jun-30-21 |
| | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q |
| Revenues | -3.4 | -1.4 | 1.5 | -2.2 | -1.6 | 0.0 | -1.6 | 15.0 |
| Revenue growth | 51.0% | -17.1% | -195.0% | -114.9% | 19.8% | | 74.5% | -1082.3% |
| Cost of goods sold | 0.0 | 0.0 | 2.7 | 0.0 | 0.0 | 2.2 | 0.0 | 1.8 |
| Gross profit | -3.4 | -1.4 | -1.2 | -2.2 | -1.6 | -2.2 | -1.6 | 13.2 |
| Gross margin | 100.0% | 100.0% | -78.0% | 100.0% | 100.0% | | 100.0% | 87.7% |
| Selling, general and administrative [+] | 4.4 | 3.9 | 4.0 | 3.9 | 3.6 | 3.8 | 3.0 | 3.0 |
| General and administrative | 4.4 | 3.9 | 4.0 | 3.9 | 3.6 | 3.8 | 3.0 | 3.0 |
| Research and development | 8.6 | 10.3 | 9.8 | 10.7 | 8.8 | 10.9 | 9.7 | 9.4 |
| EBITDA [+] | -16.4 | -15.5 | -15.0 | -16.8 | -14.0 | -16.9 | -14.2 | 0.7 |
| EBITDA growth | -2.2% | 10.4% | 5.3% | -2383.3% | 11.6% | | 18.1% | -105.6% |
| EBITDA margin | 487.1% | 1141.9% | -1000.2% | 752.2% | 857.2% | | 902.4% | 4.9% |
| Depreciation and amortization | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| EBIT [+] | -16.4 | -15.5 | -15.0 | -16.8 | -14.0 | -16.9 | -14.3 | 0.7 |
| EBIT growth | -2.2% | 10.4% | 5.3% | -2460.4% | 11.5% | | 18.1% | -105.4% |
| EBIT margin | 487.9% | 1143.2% | -1002.0% | 753.3% | 858.6% | | 903.9% | 4.7% |
| Interest income, net [+] | 0.4 | 0.6 | 0.5 | 0.2 | 0.0 | 0.0 | 0.0 | 0.1 |
| Interest expense | 0.8 | | | | | | | |
| Interest income | 1.2 | 0.6 | 0.5 | 0.2 | 0.0 | 0.0 | 0.0 | 0.1 |
| Pre-tax income | -16.0 | -15.0 | -14.6 | -16.6 | -14.0 | -16.9 | -14.2 | 0.8 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -16.0 | -15.0 | -14.6 | -16.6 | -14.0 | -16.9 | -14.2 | 0.8 |
| Net margin | 476.2% | 1102.5% | -970.4% | 746.2% | 856.2% | | 900.9% | 5.1% |
| |
| Basic EPS [+] | ($0.37) | ($0.35) | ($0.34) | ($0.39) | ($0.33) | ($0.40) | ($0.34) | $0.02 |
| Growth | -5.1% | 6.1% | 0.0% | -2050.0% | 10.0% | | -15.0% | -103.8% |
| Diluted EPS [+] | ($0.37) | ($0.35) | ($0.34) | ($0.39) | ($0.33) | ($0.40) | ($0.34) | $0.02 |
| Growth | -5.1% | 6.1% | 0.0% | -2050.0% | 10.0% | | -15.0% | -103.8% |
| |
| Shares outstanding (basic) [+] | 43.4 | 42.7 | 42.8 | 42.7 | 42.4 | 42.0 | 41.8 | 38.5 |
| Growth | 1.6% | 0.6% | 2.3% | 10.9% | 1.8% | | 39.7% | 57.2% |
| Shares outstanding (diluted) [+] | 43.4 | 42.7 | 42.8 | 42.7 | 42.4 | 42.0 | 41.8 | 38.5 |
| Growth | 1.6% | 0.6% | 2.3% | 10.9% | 1.8% | | 39.7% | 57.2% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|